Utility of patient-derived xenografts to evaluate drug sensitivity and select optimal treatments for individual non-small-cell lung cancer patients

MLA

Xiaoqing Wang, et al. “Utility of Patient-Derived Xenografts to Evaluate Drug Sensitivity and Select Optimal Treatments for Individual Non-Small-Cell Lung Cancer Patients.” Molecular Medicine, vol. 30, no. 1, Nov. 2024, pp. 1–16. EBSCOhost, https://doi.org/10.1186/s10020-024-00934-4.

APA

Xiaoqing Wang, Ju Zhu, Lingling Li, Qilin Zhao, Yutang Huang, Chunjie Wen, Dan Chen, & Lanxiang Wu. (2024). Utility of patient-derived xenografts to evaluate drug sensitivity and select optimal treatments for individual non-small-cell lung cancer patients. Molecular Medicine, 30(1), 1–16. https://doi.org/10.1186/s10020-024-00934-4

Chicago

Xiaoqing Wang, Ju Zhu, Lingling Li, Qilin Zhao, Yutang Huang, Chunjie Wen, Dan Chen, and Lanxiang Wu. 2024. “Utility of Patient-Derived Xenografts to Evaluate Drug Sensitivity and Select Optimal Treatments for Individual Non-Small-Cell Lung Cancer Patients.” Molecular Medicine 30 (1): 1–16. doi:10.1186/s10020-024-00934-4.